Below is a review of insulin sensitizer drugs appearing in the May – June, 2007 issue of Diabetes Hoy, Vol. VIII no. 3, pp. 1834-1835. Diabetes Hoy (“Diabetes Today”) is the official scientific-medical publication of the Mexican Diabetes Federation and is directed to an audience of doctors and health professionals. The review, by Dr. Roberto Gonzales, Medical Director of the Center Specialized in Diabetes (CAED), Mexico City, notes issues with and contraindications for use of the use of insulin-sensitizer drugs from the glitazone family including Avandia and Actos, as well as limitations on the use of widely used biguanide and sulfonylurea drugs. Dr. Cepeda Gonzalez’s overview concludes with a section on “a new sensitizer”, Sucanon, which Dr. Gonzales describes as having “great effectiveness and low risk”, which gives Sucanon “great potential”. A translation of Dr. Cepeda Gonzalez’s overview of Sucanon follows:
“Recently a new insulin sensitizer has been launched onto the market. This product, Sucanon, has its base and pharmacological origin in the dry extract of root of trichosanthis (trichosanthis kirilowii) and manitolatomolybdate complex. The product, which is of natural origin and has been directed towards the treatment of hyperglycemia, with its mechanism of action being based on potentiating the utilization of insulin in the cells (principally muscle cells), is considered to fall in the category of insulin sensitizers.
“The use of [this] new product of herbal origin (Sucanon) in patients with Type II Diabetes who are also obese, as well as improving the utilization of glucose by the organism, reduces weight gain, which in turn facilitates improved control in the patient with diabetes.
“In the studies which have been carried out, Sucanon, in contrast to the class of drugs known as thiazolidinediones, did not present any liver toxicity and in contrast to the biguanide drugs such as metformin, did not require restrictions when used by patients with renal insufficiency (often a complication of Type II Diabetes), which is a frequent side effect in the treatment of Type II diabetic patients, particularly those are obese.”
-- From article entitled “Sensibilizadoras de insulina” by Dr. Roberto Cepeda Gonzalez, published in Diabetes Hoy (Diabetes Today), May-June 2007, vol. 8, number 3, pp.1834-1835